No question about it: Express Scripts, the country's largest pharmacy benefit manager, just took a big hit. Shares are down about 20% since some unmistakably pessimistic language filling a recent earnings release. But is this really a reason to jump ship? In this video, Motley Fool health-care analyst Brenton Flynn outlines a trio of trends that support the bull argument for Express Scripts longer term.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.